← Back to Screener
PTC Therapeutics, Inc. (PTCT)
Price$72.32
Favorite Metrics
Price vs S&P 500 (26W)2.59%
Price vs S&P 500 (4W)0.74%
Market Capitalization$5.95B
P/E Ratio (Annual)8.72x
All Metrics
P/CF (Annual)8.37x
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)30.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)35.30%
Cash Flow / Share (Quarterly)$8.62
Price vs S&P 500 (YTD)-8.72%
Gross Margin (TTM)97.28%
Net Profit Margin (TTM)39.44%
EPS (TTM)$7.74
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$7.74
Revenue Growth (5Y)35.36%
EPS (Annual)$7.73
ROI (Annual)-44.03%
Gross Margin (Annual)97.28%
Net Profit Margin (5Y Avg)-49.93%
Cash / Share (Quarterly)$23.88
P/E Basic Excl Extra (TTM)8.72x
Revenue Growth QoQ (YoY)-22.75%
P/E Normalized (Annual)8.72x
ROA (Last FY)23.55%
Revenue Growth TTM (YoY)114.51%
EBITD / Share (TTM)$10.60
ROE (5Y Avg)-7528.34%
Operating Margin (TTM)50.09%
Cash Flow / Share (Annual)$8.62
P/B Ratio3967.67x
P/B Ratio (Quarterly)1877.27x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)4.37x
Net Interest Coverage (TTM)5.26x
ROA (TTM)25.21%
EV / EBITDA (TTM)8.55x
EPS Incl Extra (Annual)$7.73
Current Ratio (Annual)2.35x
Quick Ratio (Quarterly)2.20x
3-Month Avg Trading Volume1.18M
52-Week Price Return52.61%
EV / Free Cash Flow (Annual)10.78x
P/E Incl Extra (TTM)8.72x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$3.02
P/S Ratio (Annual)3.44x
Asset Turnover (Annual)0.60x
52-Week High$87.50
Operating Margin (5Y Avg)-34.02%
EPS Excl Extra (Annual)$7.73
CapEx CAGR (5Y)-13.06%
26-Week Price Return9.48%
Quick Ratio (Annual)2.20x
13-Week Price Return-4.39%
Total Debt / Equity (Annual)848.93x
Current Ratio (Quarterly)2.35x
Enterprise Value$7,567.852
Revenue / Share Growth (5Y)27.71%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)-63.98%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)0.91x
Pretax Margin (Annual)40.25%
Cash / Share (Annual)$23.88
3-Month Return Std Dev35.77%
Gross Margin (5Y Avg)94.16%
Net Income / Employee (TTM)$1
ROE (Last FY)-37421.43%
Net Interest Coverage (Annual)5.26x
EPS Basic Excl Extra (Annual)$7.73
P/FCF (TTM)6.85x
Receivables Turnover (TTM)10.18x
EV / Free Cash Flow (TTM)10.78x
Total Debt / Equity (Quarterly)848.93x
EPS Incl Extra (TTM)$7.74
Receivables Turnover (Annual)10.18x
ROI (TTM)-39.77%
P/S Ratio (TTM)3.44x
Pretax Margin (5Y Avg)-51.86%
Revenue / Share (Annual)$19.60
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)17.97%
P/E Ratio (TTM)8.72x
Year-to-Date Return-4.79%
5-Day Price Return-0.95%
EPS Normalized (Annual)$7.73
ROA (5Y Avg)-18.12%
Net Profit Margin (Annual)39.44%
Month-to-Date Return6.15%
Cash Flow / Share (TTM)$-6.03
EBITD / Share (Annual)$10.02
Operating Margin (Annual)50.09%
LT Debt / Equity (Annual)683.29x
P/CF (TTM)8.37x
ROI (5Y Avg)-30.54%
P/E Excl Extra (TTM)8.72x
LT Debt / Equity (Quarterly)683.29x
EPS Basic Excl Extra (TTM)$7.74
P/TBV (Quarterly)11.16x
P/B Ratio (Annual)1877.27x
Inventory Turnover (TTM)0.91x
Pretax Margin (TTM)40.25%
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)-6.77%
Beta0.62x
P/FCF (Annual)8.47x
Revenue / Share (TTM)$21.05
ROE (TTM)-351.91%
52-Week Low$35.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.91
3.95
3.95
3.81
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PTCTPTC Therapeutics, Inc. | 3.44x | 114.51% | 97.28% | — | $72.32 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
PTC Therapeutics develops and commercializes medicines for rare genetic and metabolic disorders, with a focus on neurology. The company markets several FDA-approved therapies and maintains a pipeline of clinical and preclinical candidates for pediatric and adult patients. Its diversified portfolio addresses significant unmet needs in rare disease treatment.